Journal Article10.1016/j.clinthera.2023.01.002
Artificial Intelligence and Data Mining for the Pharmacovigilance of Drug-Drug Interactions.
18
TL;DR: A wide array of intricate and elegant methods has expanded the pharmacovigilance tool kit as mentioned in this paper . But, how much they add to real prospective pharmacophigilance, reduce the public health impact of DDIs, and at what cost in terms of false alarms amplified by automation bias and its sequelae are open questions.
read more
About: This article is published in Clinical Therapeutics. The article was published on 01 Jan 2023. The article focuses on the topics: Medicine & Pharmacovigilance.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Evaluating the Sensitivity, Specificity, and Accuracy of ChatGPT-3.5, ChatGPT-4, Bing AI, and Bard Against Conventional Drug-Drug Interactions Clinical Tools
Fahmi Y. Al-Ashwal,Mohammed Zawiah,Lobna Gharaibeh,Rana Abu-Farha,Ahmad Naoras Bitar +4 more
TL;DR: Bing AI had the highest accuracy and specificity, outperforming Google’s Bard, ChatGPT-3.5, ChatgPT-4, Bing AI, and Bard in predicting drug-drug interactions and highlighting the significant potential these AI tools hold in transforming patient care.
51
Simulation-based approaches for drug delivery systems: Navigating advancements, opportunities, and challenges
Iman Salahshoori,Mahdi Golriz,Marcos A.L. Nobre,Shahla Mahdavi,Rahime Eshaghi Malekshah,Afsaneh Javdani-Mallak,Majid Namayandeh Jorabchi,Hossein Ali Khonakdar,Qilin Wang,Amir H. Mohammadi,Seyedeh Masoomeh Sadat Mirnezami,Farshad Kargaran +11 more
TL;DR: This review explores simulation techniques (MD, MC, FEA, CFD, DFT, ML, DPD) for optimizing drug delivery systems, highlighting their advantages, limitations, and future directions, including personalized medicine applications, to enhance drug delivery outcomes and patient outcomes.
30
ChatGPT in medicine: A cross-disciplinary systematic review of ChatGPT’s (artificial intelligence) role in research, clinical practice, education, and patient interaction
Aziz Fatima,Muhammad Ashir Shafique,Khadija Alam,T. Ahmed,Muhammad Saqlain Mustafa +4 more
TL;DR: This systematic review assesses ChatGPT's applications in medicine, including healthcare education, research, writing, patient communication, and clinical practice, while identifying potential limitations and areas for improvement in its use.
11
Artificial Intelligence and Big Data for Pharmacovigilance and Patient Safety
Muhammad Aasim Shamim,Muhammad Aaqib Shamim,Pankaj Arora,Pradeep Dwivedi +3 more
4
Navigating duplication in pharmacovigilance databases: a scoping review
Ronald Kiguba,Gerald Isabirye,Julius Mayengo,Jonathan Owiny,Phil Tregunno,Kendal Harrison,Munir Pirmohamed,Helen Byomire Ndagije +7 more
TL;DR: Scoping review on duplication in pharmacovigilance databases found that duplication compromises risk assessment and decision-making. Efficient prevention, detection and management strategies are needed to ensure reliable pharmacovigilance data.
2
References
DrugBank 5.0: a major update to the DrugBank database for 2018
David S. Wishart,Yannick Djoumbou Feunang,An Chi Guo,Elvis J. Lo,Ana Marcu,Jason R. Grant,Tanvir Sajed,Daniel Johnson,Carin Li,Zinat Sayeeda,Nazanin Assempour,Ithayavani Iynkkaran,Yifeng Liu,Adam Maciejewski,Nicola Gale,Alex Wilson,Lucy Chin,Ryan Cummings,Diana Le,Allison Pon,Craig Knox,Michael Wilson +21 more
TL;DR: This year’s update, DrugBank 5.0, represents the most significant upgrade to the database in more than 10 years and significant improvements have been made to the quantity, quality and consistency of drug indications, drug binding data as well as drug-drug and drug-food interactions.
7.6K
KEGG for representation and analysis of molecular networks involving diseases and drugs
TL;DR: The new disease/drug information resource named KEGG MEDICUS can be used as a reference knowledge base for computational analysis of molecular networks, especially, by integrating large-scale experimental datasets.
2.4K
The SIDER database of drugs and side effects
TL;DR: The SIDER (‘Side Effect Resource’, http://sideeffects.embl.de) database of drugs and ADRs contains a data set of drug indications, extracted from the package inserts using Natural Language Processing, used to reduce the rate of false positives by identifying medical terms that do not correspond to ADRs.
1.3K
Modeling polypharmacy side effects with graph convolutional networks.
TL;DR: Decagon is presented, an approach for modeling polypharmacy side effects that develops a new graph convolutional neural network for multirelational link prediction in multimodal networks and can predict the exact side effect, if any, through which a given drug combination manifests clinically.
1.2K
Deep learning improves prediction of drug-drug and drug-food interactions.
TL;DR: A computational framework DeepDDI is presented that accurately predicts DDI types for given drug pairs and drug–food constituent pairs using only name and structural information as inputs and can provide important information on drug prescription and even dietary suggestions while taking certain drugs and also guidelines during drug development.
523